Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial

BACKGROUND: Patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), in particular systemic sclerosis (SSc), had an attenuated response compared with idiopathic PAH in most trials. Thus, there is uncertainty regarding the benefit of PAH-targeted therapy in some f...

Descripción completa

Detalles Bibliográficos
Autores principales: Coghlan, John Gerry, Galiè, Nazzareno, Barberà, Joan Albert, Frost, Adaani E, Ghofrani, Hossein-Ardeschir, Hoeper, Marius M, Kuwana, Masataka, McLaughlin, Vallerie V, Peacock, Andrew J, Simonneau, Gérald, Vachiéry, Jean-Luc, Blair, Christiana, Gillies, Hunter, Miller, Karen L, Harris, Julia H N, Langley, Jonathan, Rubin, Lewis J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530350/
https://www.ncbi.nlm.nih.gov/pubmed/28039187
http://dx.doi.org/10.1136/annrheumdis-2016-210236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530350/
https://www.ncbi.nlm.nih.gov/pubmed/28039187
http://dx.doi.org/10.1136/annrheumdis-2016-210236

Ejemplares similares